Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10

Nature Immunology

Volumn 8, Issue 12, 2007, Pages 1363-1371

  Stumhofer, Jason S ^a   Silver, Jonathan S ^a   Laurence, Arian ^b   Porrett, Paige M ^a   Harris, Tajie H ^a   Turka, Laurence A ^a   Ernst, Matthias ^c   Saris, Christiaan J M ^d   O'Shea, John J ^b   Hunter, Christopher A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d Department of Inflammation Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HELPER CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 36248951161     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1537     Document Type: Article

References (58)

1. Fiorentino, D.F., Bond, M.W. & Mosmann, T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081-2095 (1989).
2. Moore, K.W. et al. Homology of Cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248, 1230-1234 (1990).
3. Moore, K.W., de Waal Malefyt, R., Coffman R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
4. Kuhn, R., Lohler, J, Rennick, D., Rajewsky, K. & Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993).
5. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 216 1310-1316 (2006).
6. Grunig, G. et al. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185, 1089-1099 (1997).
7. + T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157, 798-805 (106).
8. Hunter, C.A. et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J. Immunol. 158, 3311-3316 (1997).
9. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
10. + natural regulatory T cells are specific for microbial antigens. J. Exp. Med. 203, 777-788 (2006).
11. + regulatory T cells. Int. Immunol. 16, 249-256 (2004).
12. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
13. + regulatory T cells. J. Immunnol. 172, 5986-5993 (2004).
14. Del Prete, G. et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150, 353-360 (1993).
15. Gerosa, F. et al. Interleukin-12 primes human CD4 and CD8 Tcell clones for high production of both interferon-and interleukin-10. J. Exp. Med. 183, 2559-2569 (1996).
16. H1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7, 425-428 (2007).
17. Trinchieri, G. Interleukin-10 production by effector T cells: Th1 cells show self control. J. Exp. Med. 204, 239-243 (2007).
18. + T cell clones producing both interferon-γ and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin. Immunol. 92, 224-234 (1999).
19. Pohl-Koppe, A., Balashov, K.E., Steere, A.C., Logigian, E.L. & Hafler, D.A. Identification of a T cell subset capable of bath IFN-γ and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J. Immunol. 160, 1864-1810 (1998).
20. +CD25-Foxp3-Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204, 285-297 (2007).
21. +Foxp3- Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204, 273-283 (2007).
22. + T cells. Immunity 16, 779-790 (2002).
23. Chen, Q. et al. Development of Th1 -type immune responses requires the type 1 cytokine receptor TCCR. Nature 407, 916-920 (2000).
24. Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7, 929-936 (2006).
25. H17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited.by IL-27/STAT1. Nat. Med. 13, 711-718 (2007).
26. Kastelein, R.A., Hunter, C.A. & Cua, D.J. Discovery and biology of IL-23 and IL-27; related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242 (2007).
27. Villarino, A. et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19, 645-655 (2003).
28. Stumhofer, J.S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937-945 (2006).
29. Villarino, A.V. et al. Positive and negative, regulation of the IL-27 receptor during lymphoid cel activation. J. Immunol. 174 7684-7691 (2005).
30. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
31. + T cells. J. Immunol. 155, 609-618 (1995).
32. H17 and regulatory T cells. Nature 441, 235-238 (2006).
33. Neufert, C. et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol. 37, 1809-1816. (2007).
34. H17 cells. Nature 448, 484-487 (2007).
35. Chiarle, R. et al. Stat3 is required for ALK-Mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629 (2005).
36. + T cells; is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195, 603-616 (2002).
37. Hamano, S. et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19, 657-667 (2003).
38. Rosas, L.E. et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmenia donovani infection but develop severe liver immunopathology. Am. J. Pathol. 168, 158-169 (2006).
39. Wilson, E.H., Wille-Reece, U., Dzierszinski, F. & Hunter, C.A. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J. Neuroimmunol. 165, 63-44 (2005).
40. Hunter, C.A. New IL-12-fimily members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005).
41. Brightbill, H.D., Plevy, S.E., Modlin, R.L. & Smale, S.T. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J. Immunol. 164, 1940-1951 (2000),
42. Liu, Y.W., Chen, C.C., Tseng, H.P. & Chang, W.C. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-κB-induced CCAAT/enhancer-binding protein δ in mouse macrophages. Cell. Signal. 18, 1492-1500 (2006).
43. Lucas, M., Zhang, X., Prasanna, V. & Mosser, D.M. ERK activation following macrophage FcγR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175, 469-477 (2005).
44. + T cells. J. Immunol. 176, 3470-3479 (2006).
45. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 100, 15047-15052 (2003).
46. Ziegler-Heitbrock, L. et al. IFN-α induces the human IL-10 gene by recruiting bath IFN regulatory factor 1 and Stat3. J. Immunol. 171, 285-290 (2003).
47. Hou, J. et al. An interleukin-4-induced transcription factor: IL,4. Stat. Sci. 265, 1701-1706 (1994).
48. Jacobson, N.G. et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stal:4. J. Exp. Med. 181 1755-1762 (1995).
49. Chen, Z. et al. Selective regulatory function of Socs3 in the formation of IL-17- secreting T cells. Proc. Natl. Acad. Sci. USA 103, 8137-8142 (2006).
50. Mathur, A.N. et al. Stat3 and Stat4 direct develepment of IL-17-secreting Th cells. J. Immunol. 178, 4901-4907 (2007).
51. Shull, M.M. et al. Targeted disruption of the mouse transforming growth factor-βl gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
52. Espevik, T. et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J. Exp. Med. 166, 571-576 (1987).
53. Silva, J.S., Twardzik, D.R. & Reed, S-G. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor β (TGF-β). J. Exp. Med. 174, 539-545 (1991).
54. Hunter, C.A., Bermudez, L., Beernink, H., Waegell, W. &Remington J.S. Transforming growth factor-β inhibits interlukin-12-induced production of interferon-γ by natural killer cells: A role for transforming growth factor-β in the regulation of T cell-independent pesistance to Toxoplasma-gondii. Eur. J. Immunol. 25, 994-1-1000 (1995).
55. Mosmann, T.R. & Coffman, R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-178 (1989).
56. Cohen, S.B. et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum. 38, 946-952 (1995).
57. Lee, C.K. et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17, 63-72 (2002).
58. Sharma, S.D., Mullenax, J., Araujo, F.G., Erlich, H.A. & Remington, J.S. Western blot analysis of the antigens of Taxoplasma gondii recognized by human IgM and IgG antibodies. J. Immunol. 131, 977-983 (1983).